In Alzheimer’s disease, SET in the brain is translocated from the neuronal nucleus to the cytoplasm, where it inhibits PP2A activity and promotes abnormal phosphorylation of Tau (Arif et al. 2014). Here, PTPA is linked to early-onset autosomal dominant Alzheimer disease.